CHF 6563
Alternative Names: CHF6563Latest Information Update: 06 Apr 2022
At a glance
- Originator Chiesi Farmaceutici
- Class Drug withdrawal therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Opioid-related disorders
Most Recent Events
- 28 Mar 2022 Chiesi Farmaceutici terminates a Phase-II NOWSHINE clinical trial in Opioid-related disorders (In neonates) in USA, due to low patient recruitment rate (Sublingual) (NCT04104646)
- 26 Jan 2021 Phase-II clinical trials in Opioid-related disorders (In neonates) in USA (Sublingual) (NCT04104646)
- 26 Sep 2019 Chiesi Farmaceutici plans the phase II NOWSHINE trial for Opioid withdrawal syndrome (In neonates) in November 2019 (Sublingual) (NCT04104646)